The FDA approved Ascendis Pharma’s once‑weekly TransCon CNP (navepegritide) for achondroplasia, the company announced; the approval establishes a new branded treatment option for the genetic growth disorder. Ascendis positions the weekly prodrug format as a differentiated dosing approach in a market with imminent competition. Ascendis now prepares for commercialization in the U.S. while awaiting regulatory action in Europe. The approval sets up a potential multi‑player market for achondroplasia therapies and will drive payor, guideline, and pediatric endocrinology discussions about comparative efficacy, safety, and long‑term growth outcomes.